Stockreport

Baird starts Nuvalent at outperform, cites potential of lead assets [Seeking Alpha]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF The investment bank said it believes Nuvalent has “built a better mousetrap” with NVL-520 for ROS1+ lung cancer and NVL-655 for ALK+ lung cancer. It has modeled peak sa [Read more]